|
ES2577514T3
(es)
|
2005-08-22 |
2016-07-15 |
The Regents Of The University Of California |
Antagonistas de TLR
|
|
WO2007142755A2
(en)
*
|
2006-05-31 |
2007-12-13 |
The Regents Of The University Of California |
Purine analogs
|
|
EA019151B1
(ru)
|
2007-02-07 |
2014-01-30 |
Дзе Регентс Оф Дзе Юниверсити Оф Калифорния |
Конъюгаты синтетических агонистов tlr и их применение
|
|
EP2259788A4
(en)
*
|
2008-02-07 |
2011-03-16 |
Univ California |
TREATMENT OF BLADDER DISEASES WITH A TLR7 ACTIVATOR
|
|
EA026557B1
(ru)
|
2008-12-09 |
2017-04-28 |
Джилид Сайэнс, Инк. |
Промежуточные соединения для получения модуляторов толл-подобных рецепторов
|
|
KR20110117705A
(ko)
*
|
2009-02-11 |
2011-10-27 |
더 리전트 오브 더 유니버시티 오브 캘리포니아 |
톨-유사 수용체 조정제 및 질병의 치료
|
|
PE20120493A1
(es)
|
2009-06-29 |
2012-05-20 |
Incyte Corp |
Pirimidinonas como inhibidores de pi3k
|
|
US8507507B2
(en)
|
2009-10-22 |
2013-08-13 |
Gilead Sciences, Inc. |
Modulators of toll-like receptors
|
|
TW201130842A
(en)
*
|
2009-12-18 |
2011-09-16 |
Incyte Corp |
Substituted fused aryl and heteroaryl derivatives as PI3K inhibitors
|
|
US8759359B2
(en)
|
2009-12-18 |
2014-06-24 |
Incyte Corporation |
Substituted heteroaryl fused derivatives as PI3K inhibitors
|
|
AR081823A1
(es)
|
2010-04-14 |
2012-10-24 |
Incyte Corp |
DERIVADOS FUSIONADOS COMO INHIBIDORES DE PI3Kd
|
|
WO2011163195A1
(en)
|
2010-06-21 |
2011-12-29 |
Incyte Corporation |
Fused pyrrole derivatives as pi3k inhibitors
|
|
ES2764848T3
(es)
|
2010-12-20 |
2020-06-04 |
Incyte Holdings Corp |
N-(1-(fenilo sustituido)etilo)-9H-purina-6-aminas como inhibidores de PI3K
|
|
WO2012088266A2
(en)
|
2010-12-22 |
2012-06-28 |
Incyte Corporation |
Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
|
|
WO2012125629A1
(en)
|
2011-03-14 |
2012-09-20 |
Incyte Corporation |
Substituted diamino-pyrimidine and diamino-pyridine derivatives as pi3k inhibitors
|
|
WO2012135009A1
(en)
|
2011-03-25 |
2012-10-04 |
Incyte Corporation |
Pyrimidine-4,6-diamine derivatives as pi3k inhibitors
|
|
EA027792B1
(ru)
|
2011-04-08 |
2017-09-29 |
Янссен Сайенсиз Айрлэнд Юси |
Производные пиримидина для лечения вирусных инфекций
|
|
EA024063B1
(ru)
*
|
2011-05-16 |
2016-08-31 |
Ромарк Лабораториз Л.С. |
Способ стимуляции иммунного ответа путем введения тиазолидных соединений
|
|
AU2016201747B2
(en)
*
|
2011-05-16 |
2017-06-01 |
Romark Laboratories, L.C. |
Use of thiazolide compounds for the prevention and treatment of viral diseases, cancer and diseases caused by intracellular infections
|
|
KR20230038593A
(ko)
|
2011-09-02 |
2023-03-20 |
인사이트 홀딩스 코포레이션 |
Ｐｉ３ｋ 억제제로서 헤테로시클릴아민
|
|
CN104066733A
(zh)
*
|
2011-11-09 |
2014-09-24 |
爱尔兰詹森研发公司 |
用于治疗病毒感染的嘌呤衍生物
|
|
AR090548A1
(es)
|
2012-04-02 |
2014-11-19 |
Incyte Corp |
Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
|
|
HUE042374T2
(hu)
|
2012-06-13 |
2019-06-28 |
Incyte Holdings Corp |
Szubsztituált triciklusos vegyületek mint FGFR inhibitorok
|
|
SG11201408542VA
(en)
|
2012-07-13 |
2015-02-27 |
Janssen Sciences Ireland Uc |
Macrocyclic purines for the treatment of viral infections
|
|
US9388185B2
(en)
|
2012-08-10 |
2016-07-12 |
Incyte Holdings Corporation |
Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
|
|
KR102280595B1
(ko)
|
2012-10-10 |
2021-07-22 |
얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 |
바이러스 감염 및 다른 질환 치료를 위한 피롤로[3,2-d]피리미딘 유도체
|
|
CN105051018B
(zh)
|
2012-11-16 |
2019-09-20 |
爱尔兰詹森科学公司 |
用于治疗病毒性感染的杂环的经取代的2-氨基-喹唑啉衍生物
|
|
US9266892B2
(en)
|
2012-12-19 |
2016-02-23 |
Incyte Holdings Corporation |
Fused pyrazoles as FGFR inhibitors
|
|
CN105189468B
(zh)
|
2013-02-21 |
2018-10-30 |
爱尔兰詹森科学公司 |
用于治疗病毒性感染的2-氨基嘧啶衍生物
|
|
MX366481B
(es)
|
2013-03-29 |
2019-07-09 |
Janssen Sciences Ireland Uc |
Deaza-purinonas macrociclicas para el tratamiento de infecciones virales.
|
|
KR102469849B1
(ko)
|
2013-04-19 |
2022-11-23 |
인사이트 홀딩스 코포레이션 |
Fgfr 저해제로서 이환식 헤테로사이클
|
|
DK3004074T3
(da)
|
2013-05-24 |
2018-01-29 |
Janssen Sciences Ireland Uc |
Pyridonderivater til behandling af virusinfektioner og yderligere sygdomme
|
|
NO3030563T3
(enExample)
|
2013-06-27 |
2018-01-06 |
|
|
|
MX368625B
(es)
|
2013-07-30 |
2019-10-08 |
Janssen Sciences Ireland Uc |
Derivados de tieno[3,2-d]pirimidinas para el tratamiento de infecciones virales.
|
|
WO2015191677A1
(en)
|
2014-06-11 |
2015-12-17 |
Incyte Corporation |
Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors
|
|
PT3166607T
(pt)
*
|
2014-07-11 |
2022-12-07 |
Gilead Sciences Inc |
Moduladores de receptores de tipo toll para o tratamento do vih
|
|
AU2015318061B2
(en)
|
2014-09-16 |
2018-05-17 |
Gilead Sciences, Inc. |
Solid forms of a toll-like receptor modulator
|
|
US10851105B2
(en)
|
2014-10-22 |
2020-12-01 |
Incyte Corporation |
Bicyclic heterocycles as FGFR4 inhibitors
|
|
CN118286245A
(zh)
|
2014-12-26 |
2024-07-05 |
埃莫里大学 |
N4-羟基胞苷和衍生物及与其相关的抗病毒用途
|
|
MA41551A
(fr)
|
2015-02-20 |
2017-12-26 |
Incyte Corp |
Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
|
|
AU2016219822B2
(en)
|
2015-02-20 |
2020-07-09 |
Incyte Holdings Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
|
WO2016134294A1
(en)
|
2015-02-20 |
2016-08-25 |
Incyte Corporation |
Bicyclic heterocycles as fgfr4 inhibitors
|
|
PH12017501538B1
(en)
|
2015-02-27 |
2024-02-14 |
Incyte Holdings Corp |
Salts of p13k inhibitor and processes for their preparation
|
|
KR102394917B1
(ko)
|
2015-03-04 |
2022-05-09 |
길리애드 사이언시즈, 인코포레이티드 |
톨 유사 수용체 조정제 화합물
|
|
US9732097B2
(en)
|
2015-05-11 |
2017-08-15 |
Incyte Corporation |
Process for the synthesis of a phosphoinositide 3-kinase inhibitor
|
|
US9988401B2
(en)
|
2015-05-11 |
2018-06-05 |
Incyte Corporation |
Crystalline forms of a PI3K inhibitor
|
|
JP2018525412A
(ja)
|
2015-08-26 |
2018-09-06 |
ギリアード サイエンシーズ， インコーポレイテッド |
重水素化トール様受容体調節因子
|
|
CR20180321A
(es)
|
2015-12-15 |
2018-08-21 |
Gilead Sciences Inc |
Anticuerpos neutralizadores del virus de inmunodeficiencia humana
|
|
WO2017106556A1
(en)
|
2015-12-17 |
2017-06-22 |
Gilead Sciences, Inc. |
Tank-binding kinase inhibitor compounds
|
|
WO2017197046A1
(en)
|
2016-05-10 |
2017-11-16 |
C4 Therapeutics, Inc. |
C3-carbon linked glutarimide degronimers for target protein degradation
|
|
EP4491236A3
(en)
|
2016-05-10 |
2025-04-02 |
C4 Therapeutics, Inc. |
Heterocyclic degronimers for target protein degradation
|
|
CN109790143A
(zh)
|
2016-05-10 |
2019-05-21 |
C4医药公司 |
用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
|
|
EP4483875A3
(en)
|
2016-05-10 |
2025-04-02 |
C4 Therapeutics, Inc. |
Spirocyclic degronimers for target protein degradation
|
|
US11697851B2
(en)
|
2016-05-24 |
2023-07-11 |
The Regents Of The University Of California |
Early ovarian cancer detection diagnostic test based on mRNA isoforms
|
|
BR102017010009A2
(pt)
|
2016-05-27 |
2017-12-12 |
Gilead Sciences, Inc. |
Compounds for the treatment of hepatitis b virus infection
|
|
MX2018014377A
(es)
|
2016-05-27 |
2019-03-14 |
Gilead Sciences Inc |
Metodos para tratar infecciones por virus de hepatitis b usando inhibidores de proteina no estructural 5a (ns5a), proteina no estructural 5b (ns5b) o proteina no estructural 3 (ns3).
|
|
CA3027471A1
(en)
|
2016-07-01 |
2018-01-04 |
Janssen Sciences Ireland Unlimited Company |
Dihydropyranopyrimidines for the treatment of viral infections
|
|
JOP20190024A1
(ar)
|
2016-08-26 |
2019-02-19 |
Gilead Sciences Inc |
مركبات بيروليزين بها استبدال واستخداماتها
|
|
AU2017320742B2
(en)
*
|
2016-08-29 |
2021-08-05 |
F. Hoffmann-La Roche Ag |
7-substituted sulfonimidoylpurinone compounds for the treatment and prophylaxis of virus infection
|
|
WO2018045150A1
(en)
|
2016-09-02 |
2018-03-08 |
Gilead Sciences, Inc. |
4,6-diamino-pyrido[3,2-d]pyrimidine derivaties as toll like receptor modulators
|
|
PT3507276T
(pt)
|
2016-09-02 |
2022-01-11 |
Gilead Sciences Inc |
Compostos moduladores do recetor de tipo toll
|
|
US10954233B2
(en)
*
|
2016-09-09 |
2021-03-23 |
Novartis Ag |
Compounds and compositions as inhibitors of endosomal toll-like receptors
|
|
CN109790154B
(zh)
|
2016-09-29 |
2023-06-23 |
爱尔兰詹森科学公司 |
用于治疗病毒感染和另外的疾病的嘧啶前药
|
|
MA46535A
(fr)
|
2016-10-14 |
2019-08-21 |
Prec Biosciences Inc |
Méganucléases modifiées spécifiques de séquences de reconnaissance dans le génome du virus de l'hépatite b
|
|
US11117898B2
(en)
*
|
2016-11-28 |
2021-09-14 |
Jiangsu Hengrui Medicine Co., Ltd. |
Pyrazolo-heteroaryl derivative, preparation method and medical use thereof
|
|
TWI714820B
(zh)
|
2017-01-31 |
2021-01-01 |
美商基利科學股份有限公司 |
替諾福韋艾拉酚胺(tenofovir alafenamide)之晶型
|
|
JOP20180008A1
(ar)
|
2017-02-02 |
2019-01-30 |
Gilead Sciences Inc |
مركبات لعلاج إصابة بعدوى فيروس الالتهاب الكبدي b
|
|
JOP20180040A1
(ar)
|
2017-04-20 |
2019-01-30 |
Gilead Sciences Inc |
مثبطات pd-1/pd-l1
|
|
AR111960A1
(es)
|
2017-05-26 |
2019-09-04 |
Incyte Corp |
Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
|
|
WO2018237026A1
(en)
|
2017-06-20 |
2018-12-27 |
C4 Therapeutics, Inc. |
N/o-linked degrons and degronimers for protein degradation
|
|
US10494370B2
(en)
|
2017-08-16 |
2019-12-03 |
Bristol-Myers Squibb Company |
Toll-like receptor 7 (TLR7) agonists having a pyridine or pyrazine moiety, conjugates thereof, and methods and uses therefor
|
|
US10472361B2
(en)
|
2017-08-16 |
2019-11-12 |
Bristol-Myers Squibb Company |
Toll-like receptor 7 (TLR7) agonists having a benzotriazole moiety, conjugates thereof, and methods and uses therefor
|
|
US10508115B2
(en)
|
2017-08-16 |
2019-12-17 |
Bristol-Myers Squibb Company |
Toll-like receptor 7 (TLR7) agonists having heteroatom-linked aromatic moieties, conjugates thereof, and methods and uses therefor
|
|
US10487084B2
(en)
*
|
2017-08-16 |
2019-11-26 |
Bristol-Myers Squibb Company |
Toll-like receptor 7 (TLR7) agonists having a heterobiaryl moiety, conjugates thereof, and methods and uses therefor
|
|
US10457681B2
(en)
*
|
2017-08-16 |
2019-10-29 |
Bristol_Myers Squibb Company |
Toll-like receptor 7 (TLR7) agonists having a tricyclic moiety, conjugates thereof, and methods and uses therefor
|
|
JP6934562B2
(ja)
|
2017-08-22 |
2021-09-15 |
ギリアード サイエンシーズ， インコーポレイテッド |
治療用複素環式化合物
|
|
WO2019084060A1
(en)
|
2017-10-24 |
2019-05-02 |
Silverback Therapeutics, Inc. |
CONJUGATES AND METHODS OF USE FOR THE SELECTIVE DELIVERY OF IMMUNOMODULATORY AGENTS
|
|
JP2021035910A
(ja)
*
|
2017-11-01 |
2021-03-04 |
大日本住友製薬株式会社 |
置換プリン化合物
|
|
JP7382316B2
(ja)
*
|
2017-11-14 |
2023-11-16 |
ザ チルドレンズ メディカル センター コーポレーション |
ヒト免疫応答をモジュレートするためのイミダゾピリミジンの使用
|
|
CN111936136B
(zh)
|
2017-11-14 |
2024-07-05 |
儿童医学中心公司 |
新咪唑并嘧啶化合物及其用途
|
|
RS66222B1
(sr)
|
2017-12-07 |
2024-12-31 |
Univ Emory |
N4-hidroksicitidin i derivati i antivirusne upotrebe povezane sa njim
|
|
WO2019118884A1
(en)
|
2017-12-15 |
2019-06-20 |
Silverback Therapeutics, Inc. |
Antibody construct-drug conjugate for the treatment of hepatitis
|
|
AU2018392213B2
(en)
|
2017-12-20 |
2021-03-04 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
3'3' cyclic dinucleotides with phosphonate bond activating the STING adaptor protein
|
|
WO2019123339A1
(en)
|
2017-12-20 |
2019-06-27 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
2'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
|
|
CN111699187A
(zh)
|
2018-02-12 |
2020-09-22 |
豪夫迈·罗氏有限公司 |
用于治疗和预防病毒感染的新的砜化合物和衍生物
|
|
SI3752501T1
(sl)
|
2018-02-13 |
2023-08-31 |
Gilead Sciences, Inc. |
Inhibitorji pd-1/pd-l1
|
|
JP7050165B2
(ja)
|
2018-02-26 |
2022-04-07 |
ギリアード サイエンシーズ， インコーポレイテッド |
Ｈｂｖ複製阻害剤としての置換ピロリジン化合物
|
|
WO2019166432A1
(en)
*
|
2018-02-28 |
2019-09-06 |
F. Hoffmann-La Roche Ag |
7-substituted sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of liver cancer
|
|
TW201945003A
(zh)
|
2018-03-01 |
2019-12-01 |
愛爾蘭商健生科學愛爾蘭無限公司 |
２，４－二胺基喹唑啉衍生物及其醫學用途
|
|
CN110317202B
(zh)
*
|
2018-03-30 |
2021-12-24 |
江苏恒瑞医药股份有限公司 |
氰基吡咯并杂芳基类衍生物、其制备方法及其在医药上的应用
|
|
EP3774883A1
(en)
|
2018-04-05 |
2021-02-17 |
Gilead Sciences, Inc. |
Antibodies and fragments thereof that bind hepatitis b virus protein x
|
|
TW202005654A
(zh)
|
2018-04-06 |
2020-02-01 |
捷克科學院有機化學與生物化學研究所 |
２，２，─環二核苷酸
|
|
TWI833744B
(zh)
|
2018-04-06 |
2024-03-01 |
捷克科學院有機化學與生物化學研究所 |
3'3'-環二核苷酸
|
|
TWI818007B
(zh)
|
2018-04-06 |
2023-10-11 |
捷克科學院有機化學與生物化學研究所 |
2'3'-環二核苷酸
|
|
CN108295060A
(zh)
*
|
2018-04-08 |
2018-07-20 |
王长国 |
一种tlr7激动剂在增强cik细胞对肿瘤细胞杀伤力方面的应用
|
|
TW201945388A
(zh)
|
2018-04-12 |
2019-12-01 |
美商精密生物科學公司 |
對b型肝炎病毒基因體中之識別序列具有特異性之最佳化之經工程化巨核酸酶
|
|
WO2019196918A1
(zh)
*
|
2018-04-13 |
2019-10-17 |
罗欣药业(上海)有限公司 |
五元杂环并嘧啶类化合物、药物组合物及用途
|
|
CA3093130C
(en)
|
2018-04-19 |
2023-10-17 |
Gilead Sciences, Inc. |
Pd-1/pd-l1 inhibitors
|
|
WO2019209811A1
(en)
|
2018-04-24 |
2019-10-31 |
Bristol-Myers Squibb Company |
Macrocyclic toll-like receptor 7 (tlr7) agonists
|
|
TW202014193A
(zh)
|
2018-05-03 |
2020-04-16 |
捷克科學院有機化學與生物化學研究所 |
包含碳環核苷酸之2’3’－環二核苷酸
|
|
EP3788046B1
(en)
|
2018-05-04 |
2025-12-10 |
Incyte Corporation |
Salts of an fgfr inhibitor
|
|
EP4309737A3
(en)
|
2018-05-04 |
2024-03-27 |
Incyte Corporation |
Solid forms of an fgfr inhibitor and processes for preparing the same
|
|
CN110526918B
(zh)
*
|
2018-05-25 |
2021-09-03 |
江苏恒瑞医药股份有限公司 |
一种吡唑并杂芳基类衍生物的晶型及制备方法
|
|
CN110526917B
(zh)
*
|
2018-05-25 |
2021-09-03 |
江苏恒瑞医药股份有限公司 |
一种吡唑并杂芳基类衍生物的可药用盐、晶型及其制备方法
|
|
TWI704916B
(zh)
*
|
2018-05-25 |
2020-09-21 |
大陸商江蘇恒瑞醫藥股份有限公司 |
一種吡唑并雜芳基類衍生物鹽酸鹽的晶型及製備方法
|
|
CN112469418A
(zh)
|
2018-06-01 |
2021-03-09 |
因赛特公司 |
治疗pi3k相关病症的给药方案
|
|
US11168130B2
(en)
|
2018-07-03 |
2021-11-09 |
Gilead Sciences, Inc. |
Antibodies that target HIV GP120 and methods of use
|
|
WO2020010223A1
(en)
|
2018-07-06 |
2020-01-09 |
Gilead Sciences, Inc. |
Therapeutic heterocyclic compounds
|
|
EP3818052A1
(en)
|
2018-07-06 |
2021-05-12 |
Gilead Sciences, Inc. |
Therapeutic heterocyclic compounds
|
|
SI3820572T1
(sl)
|
2018-07-13 |
2023-12-29 |
Gilead Sciences, Inc. |
Inhibitorji pd-1/pd-l1
|
|
WO2020028097A1
(en)
|
2018-08-01 |
2020-02-06 |
Gilead Sciences, Inc. |
Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid
|
|
US11554120B2
(en)
|
2018-08-03 |
2023-01-17 |
Bristol-Myers Squibb Company |
1H-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (TLR7) agonists and methods and uses therefor
|
|
JP2022500414A
(ja)
|
2018-09-12 |
2022-01-04 |
シルバーバック セラピューティックス インコーポレイテッド |
免疫刺激性コンジュゲートにより疾患を処置する方法および組成物
|
|
CN111072667A
(zh)
*
|
2018-10-22 |
2020-04-28 |
罗欣药业(上海)有限公司 |
五元或六元杂环并嘧啶类化合物及其用途
|
|
JP7158577B2
(ja)
|
2018-10-24 |
2022-10-21 |
ギリアード サイエンシーズ， インコーポレイテッド |
Ｐｄ－１／ｐｄ－ｌ１阻害剤
|
|
CA3117556A1
(en)
|
2018-10-31 |
2020-05-07 |
Gilead Sciences, Inc. |
Substituted 6-azabenzimidazole compounds as hpk1 inhibitors
|
|
TWI721624B
(zh)
|
2018-10-31 |
2021-03-11 |
美商基利科學股份有限公司 |
經取代之6-氮雜苯并咪唑化合物
|
|
JP7350871B2
(ja)
|
2019-03-07 |
2023-09-26 |
インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエスシーアール，ヴイ．ヴイ．アイ． |
２’３’－環状ジヌクレオチドおよびそのプロドラッグ
|
|
EP3935065A1
(en)
|
2019-03-07 |
2022-01-12 |
Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. |
3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
|
|
WO2020178770A1
(en)
|
2019-03-07 |
2020-09-10 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
3'3'-cyclic dinucleotides and prodrugs thereof
|
|
US11628162B2
(en)
|
2019-03-08 |
2023-04-18 |
Incyte Corporation |
Methods of treating cancer with an FGFR inhibitor
|
|
HUE059677T2
(hu)
|
2019-03-22 |
2022-12-28 |
Gilead Sciences Inc |
Áthidalt triciklusos karbamoilpiridon-vegyületek és ezek gyógyszerészeti alkalmazása
|
|
TW202210480A
(zh)
|
2019-04-17 |
2022-03-16 |
美商基利科學股份有限公司 |
類鐸受體調節劑之固體形式
|
|
TWI751517B
(zh)
|
2019-04-17 |
2022-01-01 |
美商基利科學股份有限公司 |
類鐸受體調節劑之固體形式
|
|
TWI762925B
(zh)
|
2019-05-21 |
2022-05-01 |
美商基利科學股份有限公司 |
鑑別對使用gp120 v3聚醣導向之抗體的治療敏感之hiv病患的方法
|
|
EP3972695A1
(en)
|
2019-05-23 |
2022-03-30 |
Gilead Sciences, Inc. |
Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors
|
|
CA3140708A1
(en)
|
2019-06-18 |
2020-12-24 |
Helen Horton |
Combination of hepatitis b virus (hbv) vaccines and pyridopyrimidine derivatives
|
|
US20220249685A1
(en)
|
2019-06-19 |
2022-08-11 |
Silverback Therapeutics, Inc. |
Anti-mesothelin antibodies and immunoconjugates thereof
|
|
CN114245807B
(zh)
|
2019-06-25 |
2025-05-02 |
吉利德科学公司 |
Flt3l-fc融合蛋白和使用方法
|
|
TWI879779B
(zh)
|
2019-06-28 |
2025-04-11 |
美商基利科學股份有限公司 |
類鐸受體調節劑化合物的製備方法
|
|
US11591329B2
(en)
|
2019-07-09 |
2023-02-28 |
Incyte Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
|
KR20220047277A
(ko)
|
2019-07-16 |
2022-04-15 |
길리애드 사이언시즈, 인코포레이티드 |
Hiv 백신, 및 이의 제조 및 사용 방법
|
|
US20220257619A1
(en)
|
2019-07-18 |
2022-08-18 |
Gilead Sciences, Inc. |
Long-acting formulations of tenofovir alafenamide
|
|
WO2021026803A1
(en)
*
|
2019-08-14 |
2021-02-18 |
Novartis Ag |
Piperidinyl-methyl-purineamines as nsd2 inhibitors and anti-cancer agents
|
|
EP4017476A1
(en)
|
2019-08-19 |
2022-06-29 |
Gilead Sciences, Inc. |
Pharmaceutical formulations of tenofovir alafenamide
|
|
CA3150972A1
(en)
|
2019-09-19 |
2021-03-25 |
Danmarks Tekniske Universitet |
Immune stimulating micelle composition
|
|
MY208114A
(en)
|
2019-09-30 |
2025-04-16 |
Gilead Sciences Inc |
Hbv vaccines and methods treating hbv
|
|
WO2021067644A1
(en)
|
2019-10-01 |
2021-04-08 |
Silverback Therapeutics, Inc. |
Combination therapy with immune stimulatory conjugates
|
|
US12122767B2
(en)
|
2019-10-01 |
2024-10-22 |
Incyte Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
|
WO2021076602A1
(en)
|
2019-10-14 |
2021-04-22 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
WO2021076728A1
(en)
|
2019-10-16 |
2021-04-22 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
US11795223B2
(en)
|
2019-10-18 |
2023-10-24 |
Forty Seven, Inc. |
Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia
|
|
NZ786589A
(en)
|
2019-10-31 |
2025-03-28 |
Forty Seven Llc |
Anti-cd47 and anti-cd20 based treatment of blood cancer
|
|
TWI778443B
(zh)
|
2019-11-12 |
2022-09-21 |
美商基利科學股份有限公司 |
Mcl1抑制劑
|
|
KR20220131900A
(ko)
|
2019-12-04 |
2022-09-29 |
인사이트 코포레이션 |
Fgfr 억제제의 유도체
|
|
JP7720840B2
(ja)
|
2019-12-04 |
2025-08-08 |
インサイト・コーポレイション |
Ｆｇｆｒ阻害剤としての三環式複素環
|
|
CN116057068A
(zh)
|
2019-12-06 |
2023-05-02 |
精密生物科学公司 |
对乙型肝炎病毒基因组中的识别序列具有特异性的优化的工程化大范围核酸酶
|
|
MX2022007930A
(es)
|
2019-12-24 |
2022-08-08 |
Carna Biosciences Inc |
Compuestos moduladores de diacilglicerol quinasa.
|
|
US12012409B2
(en)
|
2020-01-15 |
2024-06-18 |
Incyte Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
|
US12485123B2
(en)
|
2020-01-27 |
2025-12-02 |
Bristol-Myers Squibb Company |
1H-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (TLR7) agonists
|
|
EP4097102A1
(en)
|
2020-01-27 |
2022-12-07 |
Bristol-Myers Squibb Company |
1h-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (tlr7) agonists
|
|
CN115210235A
(zh)
|
2020-01-27 |
2022-10-18 |
百时美施贵宝公司 |
作为Toll样受体7(TLR7)激动剂的1H-吡唑并[4,3-d]嘧啶化合物
|
|
CN115151548A
(zh)
|
2020-01-27 |
2022-10-04 |
百时美施贵宝公司 |
作为Toll样受体7(TLR7)激动剂的1H-吡唑并[4,3-d]嘧啶化合物
|
|
KR20220132602A
(ko)
|
2020-01-27 |
2022-09-30 |
브리스톨-마이어스 스큅 컴퍼니 |
톨-유사 수용체 7 (TLR7) 효능제로서의 1H-피라졸로[4,3-d]피리미딘 화합물
|
|
JP2023512230A
(ja)
|
2020-01-27 |
2023-03-24 |
ブリストル－マイヤーズ スクイブ カンパニー |
トール様受容体７（ＴＬＲ７）アゴニストとしてのＣ３置換１Ｈ－ピラゾロ［４，３－ｄ］ピリミジン化合物
|
|
KR20220132592A
(ko)
|
2020-01-27 |
2022-09-30 |
브리스톨-마이어스 스큅 컴퍼니 |
톨-유사 수용체 7 (TLR7) 효능제로서의 1H-피라졸로[4,3-d]피리미딘 화합물
|
|
US20230140430A1
(en)
|
2020-01-27 |
2023-05-04 |
Bristol-Myers Squibb Company |
1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS
|
|
KR20220132601A
(ko)
|
2020-01-27 |
2022-09-30 |
브리스톨-마이어스 스큅 컴퍼니 |
톨-유사 수용체 7 (TLR7) 효능제로서의 1H-피라졸로[4,3-d]피리미딘 화합물
|
|
TWI832035B
(zh)
|
2020-02-14 |
2024-02-11 |
美商基利科學股份有限公司 |
結合ccr8之抗體及融合蛋白及其用途
|
|
US11179473B2
(en)
|
2020-02-21 |
2021-11-23 |
Silverback Therapeutics, Inc. |
Nectin-4 antibody conjugates and uses thereof
|
|
WO2021188959A1
(en)
|
2020-03-20 |
2021-09-23 |
Gilead Sciences, Inc. |
Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same
|
|
EP4143194A1
(en)
|
2020-05-01 |
2023-03-08 |
Gilead Sciences, Inc. |
Cd73 inhibiting 2,4-dioxopyrimidine compounds
|
|
EP4153181A1
(en)
|
2020-05-21 |
2023-03-29 |
Gilead Sciences, Inc. |
Pharmaceutical compositions comprising bictegravir
|
|
CN116209678A
(zh)
|
2020-07-01 |
2023-06-02 |
安尔士制药公司 |
抗asgr1抗体缀合物及其用途
|
|
BR112023002164A2
(pt)
|
2020-08-07 |
2023-03-14 |
Gilead Sciences Inc |
Profármacos de análogos de nucleotídeos de fosfonamida e seu uso farmacêutico
|
|
EP4219504A4
(en)
*
|
2020-09-27 |
2024-10-16 |
Shanghai Visonpharma Co., Ltd. |
MACROCYCLIC TLR7 AGONIST, MANUFACTURING METHOD THEREOF, PHARMACEUTICAL COMPOSITION AND USE THEREOF
|
|
TWI815194B
(zh)
|
2020-10-22 |
2023-09-11 |
美商基利科學股份有限公司 |
介白素2-Fc融合蛋白及使用方法
|
|
CA3195799A1
(en)
|
2020-11-11 |
2022-05-19 |
Stephen R. Martin |
Methods of identifying hiv patients sensitive to therapy with gp120 cd4 binding site-directed antibodies
|
|
KR102514860B1
(ko)
*
|
2020-12-01 |
2023-03-29 |
한국과학기술연구원 |
5-ht7 세로토닌 수용체 활성 저해용 바이페닐 피롤리딘 및 바이페닐 다이하이드로이미다졸 유도체 및 이를 유효성분으로 포함하는 약학 조성물
|
|
TW202304524A
(zh)
|
2021-04-10 |
2023-02-01 |
美商普方生物製藥美國公司 |
Folr1結合劑、其結合物及使用方法
|
|
CA3215903A1
(en)
|
2021-04-12 |
2022-10-20 |
Incyte Corporation |
Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
|
|
TW202302145A
(zh)
|
2021-04-14 |
2023-01-16 |
美商基利科學股份有限公司 |
ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症
|
|
AU2022262644A1
(en)
|
2021-04-23 |
2023-11-09 |
Genmab A/S |
Anti-cd70 antibodies, conjugates thereof and methods of using the same
|
|
TW202348237A
(zh)
|
2021-05-13 |
2023-12-16 |
美商基利科學股份有限公司 |
TLR8調節化合物及抗HBV siRNA療法之組合
|
|
TW202313094A
(zh)
|
2021-05-18 |
2023-04-01 |
美商基利科學股份有限公司 |
使用ＦＬＴ３Ｌ—Ｆｃ融合蛋白之方法
|
|
WO2022261159A1
(en)
|
2021-06-09 |
2022-12-15 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
|
EP4352059A1
(en)
|
2021-06-09 |
2024-04-17 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
|
AU2022298639C1
(en)
|
2021-06-23 |
2025-07-17 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
|
EP4359389A1
(en)
|
2021-06-23 |
2024-05-01 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
|
CA3222277A1
(en)
|
2021-06-23 |
2022-12-29 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
|
JP7686091B2
(ja)
|
2021-06-23 |
2025-05-30 |
ギリアード サイエンシーズ， インコーポレイテッド |
ジアシルグリセロールキナーゼ調節化合物
|
|
TW202320857A
(zh)
|
2021-07-06 |
2023-06-01 |
美商普方生物製藥美國公司 |
連接子、藥物連接子及其結合物及其使用方法
|
|
CA3234909A1
(en)
|
2021-10-28 |
2023-05-04 |
Gilead Sciences, Inc. |
Pyridizin-3(2h)-one derivatives
|
|
JP2024541979A
(ja)
|
2021-10-29 |
2024-11-13 |
ギリアード サイエンシーズ， インコーポレイテッド |
Ｃｄ７３化合物
|
|
EP4440702B1
(en)
|
2021-12-03 |
2025-05-21 |
Gilead Sciences, Inc. |
Therapeutic compounds for hiv virus infection
|
|
US12084467B2
(en)
|
2021-12-03 |
2024-09-10 |
Gilead Sciences, Inc. |
Therapeutic compounds for HIV virus infection
|
|
JP7736929B2
(ja)
|
2021-12-03 |
2025-09-09 |
ギリアード サイエンシーズ， インコーポレイテッド |
Ｈｉｖウイルス感染症のための治療化合物
|
|
WO2023107956A1
(en)
|
2021-12-08 |
2023-06-15 |
Dragonfly Therapeutics, Inc. |
Proteins binding nkg2d, cd16 and 5t4
|
|
US20230220106A1
(en)
|
2021-12-08 |
2023-07-13 |
Dragonfly Therapeutics, Inc. |
Antibodies targeting 5t4 and uses thereof
|
|
KR20240125012A
(ko)
|
2021-12-22 |
2024-08-19 |
길리애드 사이언시즈, 인코포레이티드 |
이카로스 아연 핑거 패밀리 분해제 및 이의 용도
|
|
CN118488946A
(zh)
|
2021-12-22 |
2024-08-13 |
吉利德科学公司 |
Ikaros锌指家族降解剂及其用途
|
|
TW202340168A
(zh)
|
2022-01-28 |
2023-10-16 |
美商基利科學股份有限公司 |
Ｐａｒｐ７抑制劑
|
|
KR20230130479A
(ko)
*
|
2022-03-03 |
2023-09-12 |
서울대학교병원 |
안구건조증 또는 마이봄샘 기능장애의 예방, 개선, 또는 치료용 조성물
|
|
DK4245756T3
(da)
|
2022-03-17 |
2024-10-21 |
Gilead Sciences Inc |
Ikaros zinkfinger-familiens nedbrydere og anvendelse heraf
|
|
US20230355796A1
(en)
|
2022-03-24 |
2023-11-09 |
Gilead Sciences, Inc. |
Combination therapy for treating trop-2 expressing cancers
|
|
TWI876305B
(zh)
|
2022-04-05 |
2025-03-11 |
美商基利科學股份有限公司 |
用於治療結腸直腸癌之組合療法
|
|
TWI843506B
(zh)
|
2022-04-06 |
2024-05-21 |
美商基利科學股份有限公司 |
橋聯三環胺甲醯基吡啶酮化合物及其用途
|
|
IL316058A
(en)
|
2022-04-21 |
2024-11-01 |
Gilead Sciences Inc |
Compounds modulate KRAS G12D
|
|
WO2024006982A1
(en)
|
2022-07-01 |
2024-01-04 |
Gilead Sciences, Inc. |
Therapeutic compounds useful for the prophylactic or therapeutic treatment of an hiv virus infection
|
|
CR20240570A
(es)
|
2022-07-01 |
2025-03-03 |
Gilead Sciences Inc |
Compuestos de cd73
|
|
AU2023307100A1
(en)
|
2022-07-12 |
2025-01-02 |
Gilead Sciences, Inc. |
Hiv immunogenic polypeptides and vaccines and uses thereof
|
|
US20240083984A1
(en)
|
2022-08-26 |
2024-03-14 |
Gilead Sciences, Inc. |
Dosing and scheduling regimen for broadly neutralizing antibodies
|
|
WO2024064668A1
(en)
|
2022-09-21 |
2024-03-28 |
Gilead Sciences, Inc. |
FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY
|
|
US20240226130A1
(en)
|
2022-10-04 |
2024-07-11 |
Gilead Sciences, Inc. |
4'-thionucleoside analogues and their pharmaceutical use
|
|
KR20250122479A
(ko)
|
2022-12-22 |
2025-08-13 |
길리애드 사이언시즈, 인코포레이티드 |
Prmt5 억제제 및 이의 용도
|
|
US20240383922A1
(en)
|
2023-04-11 |
2024-11-21 |
Gilead Sciences, Inc. |
KRAS Modulating Compounds
|
|
AR132464A1
(es)
|
2023-04-19 |
2025-07-02 |
Gilead Sciences Inc |
Régimen de dosificación de inhibidor de la cápside
|
|
AU2024259556A1
(en)
|
2023-04-21 |
2025-10-23 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
WO2024249573A1
(en)
|
2023-05-31 |
2024-12-05 |
Gilead Sciences, Inc. |
Solid forms of compounds useful in the treatment of hiv
|
|
TW202448483A
(zh)
|
2023-05-31 |
2024-12-16 |
美商基利科學股份有限公司 |
用於ｈｉｖ之治療性化合物
|
|
CN116496277B
(zh)
*
|
2023-06-14 |
2023-08-25 |
齐泽(云南)生物科技有限公司 |
一种姜黄素2,6-二氨基嘌呤衍生化合物
|
|
CN116444522B
(zh)
*
|
2023-06-14 |
2023-08-25 |
齐泽(云南)生物科技有限公司 |
一种姜黄素腺嘌呤衍生化合物
|
|
WO2025006720A1
(en)
|
2023-06-30 |
2025-01-02 |
Gilead Sciences, Inc. |
Kras modulating compounds
|
|
US20250100998A1
(en)
|
2023-07-26 |
2025-03-27 |
Gilead Sciences, Inc. |
Parp7 inhibitors
|
|
WO2025024663A1
(en)
|
2023-07-26 |
2025-01-30 |
Gilead Sciences, Inc. |
Parp7 inhibitors
|
|
WO2025029247A1
(en)
|
2023-07-28 |
2025-02-06 |
Gilead Sciences, Inc. |
Weekly regimen of lenacapavir for the treatment and prevention of hiv
|
|
WO2025042394A1
(en)
|
2023-08-23 |
2025-02-27 |
Gilead Sciences, Inc. |
Dosing regimen of hiv capsid inhibitor
|
|
US20250109147A1
(en)
|
2023-09-08 |
2025-04-03 |
Gilead Sciences, Inc. |
Kras g12d modulating compounds
|
|
WO2025054347A1
(en)
|
2023-09-08 |
2025-03-13 |
Gilead Sciences, Inc. |
Kras g12d modulating compounds
|
|
WO2025072406A1
(en)
|
2023-09-26 |
2025-04-03 |
Profoundbio Us Co. |
Ptk7 binding agents, conjugates thereof and methods of using the same
|
|
TW202530226A
(zh)
|
2023-10-11 |
2025-08-01 |
美商基利科學股份有限公司 |
橋聯三環胺甲醯基吡啶酮化合物及其用途
|
|
TW202515549A
(zh)
|
2023-10-11 |
2025-04-16 |
美商基利科學股份有限公司 |
橋聯三環胺甲醯基吡啶酮化合物及其用途
|
|
WO2025080863A1
(en)
|
2023-10-11 |
2025-04-17 |
Gilead Sciences, Inc. |
Bridged tricyclic carbamoylpyridone compounds and uses thereof
|
|
US20250154172A1
(en)
|
2023-11-03 |
2025-05-15 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
US20250230168A1
(en)
|
2023-12-22 |
2025-07-17 |
Gilead Sciences, Inc. |
Azaspiro wrn inhibitors
|
|
WO2025137245A1
(en)
|
2023-12-22 |
2025-06-26 |
Gilead Sciences, Inc. |
Solid forms of hiv integrase inhibitors
|
|
US20250296992A1
(en)
|
2024-01-10 |
2025-09-25 |
Genmab A/S |
Slitrk6 binding agents, conjugates thereof and methods of using the same
|
|
WO2025181219A1
(en)
|
2024-02-29 |
2025-09-04 |
Genmab A/S |
Egfr and c-met bispecific binding agents, conjugates thereof and methods of using the same
|
|
US20250289822A1
(en)
|
2024-03-01 |
2025-09-18 |
Gilead Sciences, Inc. |
Solid forms of hiv integrase inhibitors
|
|
US20250333424A1
(en)
|
2024-03-01 |
2025-10-30 |
Gilead Sciences, Inc. |
Antiviral compounds
|
|
WO2025184447A1
(en)
|
2024-03-01 |
2025-09-04 |
Gilead Sciences, Inc. |
Pharmaceutical compositions comprising hiv integrase inhibitors
|
|
WO2025240244A1
(en)
|
2024-05-13 |
2025-11-20 |
Gilead Sciences, Inc. |
Combination therapies comprising bulevirtide and lonafarnib for use in the treatment of hepatitis d virus infection
|
|
WO2025240242A1
(en)
|
2024-05-13 |
2025-11-20 |
Gilead Sciences, Inc. |
Combination therapies with ribavirin
|
|
WO2025240246A1
(en)
|
2024-05-13 |
2025-11-20 |
Gilead Sciences, Inc. |
Combination therapies with ribavirin
|
|
US20250345389A1
(en)
|
2024-05-13 |
2025-11-13 |
Gilead Sciences, Inc. |
Combination therapies
|
|
WO2025245003A1
(en)
|
2024-05-21 |
2025-11-27 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|